Six months after patients switched from reference infliximab to biosimilar infliximab, there was no meaningful increase in patients’ outpatient healthcare use, according to a new study.
While switching medically stable patients from reference biologics to cheaper biosimilars has the potential to generate significant cost savings for health systems, some recent studies have suggested that these nonmedical switches could actually lead to higher costs because of increased healthcare utilization.
A study published this month in RMD Open sought to examine whether a large, mandatory nonmedical switch to a biosimilar in Danish patients with inflammatory arthritis changed their resource utilization, and found that, 6 months after switching, there was no meaningful increase in patients’ outpatient healthcare use.
In May 2015, Danish national guidelines mandated a switch from reference infliximab, Remicade, to biosimilar CT-P13 (sold as Inflectra in the United States and as Remsima in other territories) in order to benefit from the 36% lower cost of the biosimilar. The DANBIO registry, which collects clinical information among all Danish patients with inflammatory diseases, offered a chance for investigators to assess healthcare utilization 6 months pre- and 6 months postswitch.
The study population included 769 patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who switched from the reference to the biosimilar infliximab in 2016. The patients had a total of 2995 visits to healthcare providers in the 6 months before switching, 689 visits on the date of switching, and 3034 visits up to 6 months after the switch. In total, 19,752 services (such as consultation, guidance, administration of infliximab or methotrexate, observation, and similar services) were provided to patients, 2019 of which were provided on the switch date. The weekly rate of visits per patient was stable during the full time period investigated.
The total number of days with services provided in the preswitch period was 4131, and in the postswitch period, 4400. Rates of services provided declined after switching, but there was an increase in telephone consultation, patient guidance, intravenous medication, clinical investigation and controls, and patient observation. However, the numerical differences in services provided were close to zero.
The authors concluded that their study showed no evidence of increased outpatient healthcare utilization following the nationwide switch.
“It is reassuring that we found only minor changes in the use of healthcare resources, despite the switch being mandatory and that no specific strategy for patient information was set up,” and they indicated that “the fact that patients were informed about the switch at an already scheduled appointment could potentially reduce the nocebo effect.”
Reference
Glintborg B, Sørensen, Hetland ML. Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis. RMD Open. 2018;4(2): e000710. doi: 10.1136/rmdopen-2018-000710.
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.